The lawsuit alleges that Zoetis executives touted growth and veterinarian adoption for flagship products while failing to disclose critical setbacks. According to the complaint, demand for the canine pain treatment Librela weakened significantly following FDA warnings about neurological complications. Simultaneously, the company's Simparica Trio and dermatology treatments, Apoquel and Cytopoint, reportedly faced mounting pressure from lower-priced or newly launched competitors in a cooling market.

Investors who purchased shares during the specified period may be eligible for compensation under a contingency fee arrangement, meaning no out-of-pocket costs are required to participate. While the court has not yet certified a class, those wishing to direct the litigation as lead plaintiff must file their motions by July 27, 2026. Interested parties can contact Phillip Kim at the Rosen Law Firm to review their options or join the ongoing proceedings.